140 related articles for article (PubMed ID: 11267255)
1. CMV in kidney transplants in the tacrolimus-mycophenolate era.
Cailhier JF; Boucher A; Béliveau C; Poirier L; Delorme J; Weiss K; Laverdière M; Hébert MJ; Pichette V; Dandavino R
Transplant Proc; 2001; 33(1-2):1196-7. PubMed ID: 11267255
[No Abstract] [Full Text] [Related]
2. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone.
Lo A; Stratta RJ; Egidi MF; Kizilisik AT; Shokouh-Amiri MH; Grewal HP; Trofe J; Alloway RR; Gaber AO
Transplant Proc; 2001; 33(1-2):1796-8. PubMed ID: 11267516
[No Abstract] [Full Text] [Related]
3. Cytomegalovirus risk factors in renal transplantation with modern immunosuppression.
Bataille S; Moal V; Gaudart J; Indreies M; Purgus R; Dussol B; Zandotti C; Berland Y; Vacher-Coponat H
Transpl Infect Dis; 2010 Dec; 12(6):480-8. PubMed ID: 20629971
[TBL] [Abstract][Full Text] [Related]
4. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay.
Cirocco RE; Ciancio G; Esquenazi V; Burke GW; Miller J
Transplant Proc; 1999; 31(1-2):1362-3. PubMed ID: 10083604
[No Abstract] [Full Text] [Related]
5. Effect of mycophenolate mofetil on the Anti-CMV serologic response after renal transplantation.
Hardwick LL; Savatta SG; Book BK; Milgrom ML; McQueen J; Anderson M; Filo RS; Leapman SB; Pescovitz MD
Transplant Proc; 2001; 33(1-2):1865-6. PubMed ID: 11267545
[No Abstract] [Full Text] [Related]
6. The use of sirolimus in patients with recurrent cytomegalovirus infection after kidney transplantation: A retrospective case series analysis.
Shendi AM; Hung RKY; Caplin B; Griffiths P; Harber M
Saudi J Kidney Dis Transpl; 2019; 30(3):606-614. PubMed ID: 31249224
[TBL] [Abstract][Full Text] [Related]
7. Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil.
Brum S; Nolasco F; Sousa J; Ferreira A; Possante M; Pinto JR; Barroso E; Santos JR
Transplant Proc; 2008 Apr; 40(3):752-4. PubMed ID: 18455007
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of recurrent cytomegalovirus infection in kidney transplant recipients.
Nafar M; Roshan A; Pour-Reza-Gholi F; Samadian F; Ahmadpoor P; Samavat S; Abbasi MA
Iran J Kidney Dis; 2014 May; 8(3):231-5. PubMed ID: 24878947
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients.
Sarmiento JM; Dockrell DH; Schwab TR; Munn SR; Paya CV
Clin Transplant; 2000 Apr; 14(2):136-8. PubMed ID: 10770418
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
[TBL] [Abstract][Full Text] [Related]
12. [Atypical cytomegalovirus in renal transplantation: a new form of presentation].
Pérez-Valentín MA; Cofán F; Solé M; Llach J; Esforzado N; Campistol JM; Oppenheimer F
Nefrologia; 2002; 22(4):381-5. PubMed ID: 12369131
[TBL] [Abstract][Full Text] [Related]
13. Failure of ganciclovir prophylaxis of primary cytomegalovirus disease in immunologic high-risk recipients.
Conti DJ; Isenberg A; Shen GK; Hahn A; Singh TP
Transplant Proc; 1998 Jun; 30(4):1314-5. PubMed ID: 9636533
[No Abstract] [Full Text] [Related]
14. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus colitis during mycophenolate mofetil therapy for Wegener's granulomatosis.
Woywodt A; Choi M; Schneider W; Kettritz R; Göbel U
Am J Nephrol; 2000; 20(6):468-72. PubMed ID: 11146314
[TBL] [Abstract][Full Text] [Related]
16. [Cytomegalovirus infection in transplant recipients].
Gondo H
Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
[TBL] [Abstract][Full Text] [Related]
17. Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease.
Sarmiento E; Fernàndez-Yáñez J; Muñoz P; Palomo J; Rodríguez-Molina JJ; Bermejo J; Catalan P; Bouza E; Fernández-Cruz E; Carbone J
Int Immunopharmacol; 2005 Jan; 5(1):97-101. PubMed ID: 15589466
[TBL] [Abstract][Full Text] [Related]
18. Mycophenolate mofetil immunosuppressive therapies increase the incidence of cytomegalovirus infection in renal transplantation.
Munoz MA; Andrés A; Gallego R; Morales E; Morales JM; Aguado JM; Lumbreras C; Torres A; Rodicio JL; Praga M
Transplant Proc; 2002 Feb; 34(1):97. PubMed ID: 11959202
[No Abstract] [Full Text] [Related]
19. Opportunistic infections in myasthenia gravis treated with mycophenolate mofetil.
Termsarasab P; Katirji B
J Neuroimmunol; 2012 Aug; 249(1-2):83-5. PubMed ID: 22613699
[TBL] [Abstract][Full Text] [Related]
20. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
